What do systematic reviews say?

Intervention not reported

The intervention showed no clear difference in grade 3/4 cardiotoxicity (low certainty).

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  RR 0.67 [0.11, 3.88]
  1 study · 160 participants
  Low

Intervention not reported

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Intervention not reported

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Intervention not reported

The intervention showed no clear difference in mortality/relapse at 2 years (low certainty).

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  HR 0.62 [0.34, 1.14]
  1 study · 63 participants
  Low

Intervention not reported

The intervention may leads to higher complete remission (low certainty).

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  RR 1.28 [1.03, 1.59]
  2 studies · 187 participants
  Low

Intervention not reported

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Intervention not reported

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Intervention not reported

The intervention probably leads to lower mortality/relapse at 2 years (moderate certainty).

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  HR 0.88 [0.81, 0.96]
  8 studies · 3070 participants
  Moderate

Intervention not reported

It is very uncertain whether the intervention changes grade 3/4 cardiotoxicity (very low certainty).

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  RR 0.31 [0.01, 7.39]
  1 study · 100 participants
  Very low

Intervention not reported

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Intervention not reported

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Intervention not reported

The intervention showed no clear difference in mortality/relapse at 2 years (low certainty).

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  HR 1.25 [0.83, 1.88]
  1 study · 155 participants
  Low

Intervention not reported

The intervention showed no clear difference in complete remission (low certainty).

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  RR 1.04 [0.96, 1.13]
  2 studies · 964 participants
  Low

Intervention not reported

The intervention showed no clear difference in death on induction therapy (moderate certainty).

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  RR 0.75 [0.5, 1.13]
  2 studies · 964 participants
  Moderate

Intervention not reported

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Intervention not reported

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Intervention not reported

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Intervention not reported

The intervention probably leads to higher complete remission (moderate certainty).

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  RR 1.04 [1.01, 1.07]
  18 studies · 6692 participants
  Moderate

Intervention not reported

The intervention probably leads to higher death on induction therapy (moderate certainty).

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  RR 1.18 [1.01, 1.36]
  14 studies · 6349 participants
  Moderate

Intervention not reported

The intervention probably leads to lower relapse (moderate certainty).

• The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia 2015 · Cochrane Headline outcomes only
  RR 0.88 [0.8, 0.98]
  4 studies · 1091 participants
  Moderate